Treatment of Steroid-Refractory Immune Checkpoint-Related Hepatitis With Ruxolitinib

ACG Case Reports Journal 2026 Open access

Read full text
Authors: V V Nguyen, Malcolm M. Wells, Carlos Moctezuma‐Velázquez, Matthew Anaka, John Walker, Ellina Lytvyak, Puneeta Tandon, Rahima A. Bhanji, Montano-Loza Aldo
DOI: 10.14309/crj.0000000000002008
Cited by: 0
References: 14

Abstract

The incidence of immune-related hepatitis (IRH) is rising due to increasing use of immune checkpoint inhibitors for the treatment of several malignancies. While most cases respond to corticosteroid therapy, some patients require additional immunosuppressive agents, for which evidence to guide management is still evolving. We present the first documented case of ruxolitinib use as a tertiary agent for IRH following failure of corticosteroids and tocilizumab, suggesting a potential role for Janus kinase inhibitors as a rescue therapy for severe IRH.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Drug-Induced Hepatotoxicity and Protection IgG4-Related and Inflammatory Diseases

Publication details

Journal / source
ACG Case Reports Journal
Volume
13
Issue
2
Pages
e02008–e02008
Publication date
1 February 2026
Language
EN